Illumina Launches Advanced Liquid Biopsy Assay To Enable Comprehensive Genomic Profiling Of Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Illumina Inc. (NASDAQ:ILMN) has announced a new generation of its liquid biopsy assay for genomic profiling, TruSight™ Oncology 500 ctDNA v2 (TSO 500 ctDNA v2). The assay enables noninvasive comprehensive genomic profiling of circulating tumor DNA from blood. Improvements include a faster sample-to-answer turnaround time of less than four days, higher sensitivity with lower cell-free DNA input requirements, and a more streamlined workflow. Automation is expected in the first half of 2024.
November 01, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Illumina's new liquid biopsy assay, TSO 500 ctDNA v2, could potentially increase the company's market share in the genomic profiling sector due to its improved features and expected automation in 2024.
The launch of Illumina's new liquid biopsy assay, which offers faster turnaround time, higher sensitivity, and a more streamlined workflow, could potentially attract more customers and increase the company's revenues. The expected automation in 2024 could further enhance the product's appeal and efficiency, potentially leading to a positive impact on Illumina's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100